Efficacy of intravenous reslizumab in oral corticosteroid-dependent asthma

We report post hoc analyses of pooled data from duplicate, placebo-controlled Phase 3 trials. Patients aged 12–75 with inadequately controlled, moderate-to-severe asthma were randomized 1:1 to receive intravenous reslizumab 3.0 mg/kg or placebo every 4 weeks for 52 weeks, stratified by oral corticosteroid use at enrollment and by region. Assessments included efficacy and predictors of clinical asthma exacerbation response in oral corticosteroid-dependent patients, and systemic corticosteroids burden in the overall population.RESULTSPatients were randomized to reslizumab (n = 477) or placebo (n = 476); 73 (15%) patients in each group were taking oral corticosteroids at baseline. Reslizumab was favored over placebo for all efficacy endpoints in oral corticosteroid-dependent patients, with numerically greater improvements in oral corticosteroid-dependent patients than the overall population. Having ≥ 2 versus 1 clinical asthma exacerbation in the previous 12 months was the strongest positive predictor of reduced exacerbation risk with reslizumab (risk reduction 77.5% vs. 15.2%; P ≤ 0.02). Significantly fewer new systemic corticosteroid prescriptions were issued per patient receiving reslizumab versus placebo (mean [standard deviation]: 0.5 [1.07] vs. 1.0 [1.52]; P
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research

Related Links:

CONCLUSIONS: Irrespective of the type of allergen, long-term maintenance AIT helps to spare ICS dose and achieve better control in patients with allergic asthma in real-world clinical practice. PMID: 31743967 [PubMed]
Source: Allergy, Asthma and Immunology Research - Category: Allergy & Immunology Tags: Allergy Asthma Immunol Res Source Type: research
The complexity of asthma is underscored by the number of cell types and mediators implicated in the pathogenesis of this heterogeneous syndrome. Type 2 CD4+ T-cells (Th2) and more recently, type 2 innate lymphoid cells dominate current descriptions of asthma pathogenesis. However, another important source of these type 2 cytokines, especially interleukin (IL)-5 and IL-13, are CD8+ T-cells, which are increasingly proposed to play an important role in asthma pathogenesis, because they are abundant and are comparatively insensitive to corticosteroids. Many common triggers of asthma exacerbations are mediated via corticosteroi...
Source: European Respiratory Review - Category: Respiratory Medicine Authors: Tags: Asthma and allergy Reviews Source Type: research
AbstractPurpose of this reviewTo highlight the evidence behind the various biologics that are being developed for asthma along with their specific targets in the inflammatory cascade and the potential role they serve in the management of allergic asthma.Recent findingsThe mainstay of asthma management for the majority of asthmatics is inhaled corticosteroids with or without long-acting beta-agonists and/or leukotriene modifiers and/or tiotropium. However, in the small group of individuals with severe asthma uncontrolled with conventional therapy, biologics have emerged as an effective therapeutic option.SummaryAsthma is a ...
Source: Current Treatment Options in Allergy - Category: Allergy & Immunology Source Type: research
This study suggests that a simple risk-assessment tool could potentially be created for emergency rooms in similar settings to identify higher-risk children on whom limited resources might be better focused.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Asthma and allergy Original Articles: Asthma Source Type: research
Abstract BACKGROUND: GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid). OBJECTIVE: To evaluate efficacy and safety of GSP301 in patients with seasonal AR (SAR). METHODS: In this phase 2, double-blind, parallel-group study, patients (≥12 years of age) with SAR were equally randomized to twice-daily GSP301 (olopatadine 665μg and mometasone 25μg), once-daily GSP301 (olopatadine 665μg and mometasone 50μg), twice-daily or once-daily olopatadine monotherapy (665μg), mometasone monotherapy (twice...
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Ann Allergy Asthma Immunol Source Type: research
GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid).
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
Publication date: Available online 11 November 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Marcello Cottini, Anita Licini, Carlo Lombardi, Alvise BertiAbstractBackgroundThe involvement of small airways has recently gained greater recognition in asthma. Impulse oscillometry (IOS) is a simple and noninvasive method based on the forced oscillation technique, for the detection of small airway dysfunction (SAD).ObjectiveWe aimed to identify the predictors of SAD in an unselected sample of 400 patients with physician-diagnosed asthma.MethodsAll patients underwent standard spirometry and IOS ...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
ConclusionChildren with asthma with exacerbations compared to asthma children without exacerbations are characterized by increased airway obstruction since infancy through childhood. The airway obstruction is a fixed trajectory without progression due to exacerbations, suggesting that exacerbations are a consequence rather than a cause of diminished airway caliber in childhood.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: Available online 8 November 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): David Langton, Wei Wang, Joy Sha, Alvin Ing, David Fielding, Nicole Hersch, Virginia Plummer, Francis ThienAbstractBackgroundWhilst it is established that not all patients respond to bronchial thermoplasty (BT), the factors that predict response/non-response are largely unknown.ObjectivesThe aim of this study was to identify baseline factors that predict clinical response.MethodsThe records of 77 consecutive patients entered into the Australian Bronchial Thermoplasty Register were examined for bas...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
AbstractPurpose of This ReviewTo highlight the evidence behind the various approved biologics indicated for asthma along with their specific targets in the inflammatory cascade and the role they serve in the management of allergic asthma.Recent FindingsThe mainstay of asthma management for the majority of asthmatics is inhaled corticosteroids with or without long-acting beta-agonists and/or leukotriene modifiers and/or tiotropium. However, in the small group of individuals with severe asthma uncontrolled with conventional therapy, biologics have emerged as an effective therapeutic option.SummaryAsthma is a chronic heteroge...
Source: Current Treatment Options in Allergy - Category: Allergy & Immunology Source Type: research
More News: Allergy | Allergy & Immunology | Asthma | Corticosteroid Therapy